Belgium's CHIM Momentum: Faster Timelines, New RSV Model

Early efficacy data shapes confidence, yet traditional paths take too long. With Belgium reopening a faster, predictable 59-day approval timeline and SGS Clinical Research adding the new RSV-A challenge model to their CHIM portfolio in Antwerp, the landscape is shifting in your favour.

This webinar shows what that shift means for your program and how running CHIM studies in Antwerp helps you move with more speed and less dependency.

You will learn how a modern CHIM approach, Antwerp’s integrated setup and Belgium’s faster timeline, gives you the early efficacy signals your investors trust. You will also see how this structure removes delays and brings you to POC sooner.

Agenda

• Why CHIM accelerates POC
• What makes Antwerp Europe’s CHIM hub
• Updated Belgian regulatory timelines
• Deep dive: the H3N2 and the new RSV-A challenge models
• Live Q&A

Who should attend?

The webinar is designed for biotech and pharma teams in early clinical respiratory development, including CSOs, CMOs, clinical program leads and scientific directors seeking faster, data-driven proof of concept to guide development strategy.

Register now

This event takes place on January 22, 2026 at 03:00 PM CET.